Effect of Dosing Frequency on Chronic Cardiovascular Disease Medication Adherence

Coleman, Craig I; Roberts, Matthew; Sobieraj, Diana M; Lee, Soyon; Alam, Tawfikul; Kaur, Rajbir

doi:10.1016/s0735-1097(12)61809-9

Cited by 44 publications

(62 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study only 43% of patients with AF associated with HT, IHD and CHF had good treatment compliance. Similar results were demonstrated in other trials where medical adherence in chronically ill patients was about 50% [21]. In this case, development and implementation of algorithms for regular compliance evaluation is crucial in everyday clinical practice.…”

Section: Oral Anticoagulants In Ambulatory and In-hospital Treatment supporting

confidence: 84%

Oral Anticoagulants in Ambulatory and in-Hospital Treatment of Patients With Atrial Fibrillation Associated With Hypertension, Ischemic Heart Disease and Chronic Heart Failure: Data From Hospital Registry Recvasa-Clinic

Stepina¹,

Lukyanov²,

Бичурина³

et al. 2017

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim.To estimate the rate of oral anticoagulants (OAC) prescription, continuity of anticoagulant therapy in hospital and ambulatory stages along with treatment adherence in patients with atrial fibrillation (AF) associated with hypertension (HT), ischemic heart disease (IHD) and chronic heart failure (CHF) within the registry of cardiovascular diseases. Material and methods. The study included 285 patients with AF combined with HT, IHD and CHF from the hospital registry RECVASA-CLINIC (n=3696). The rate of OAC prescription was evaluated in ambulatory and in-hospital stages according to medical records. Out-patient treatment was estimated via phone contact in 250 participants that represented 96.2% of all survived patients during follow-up of 24.1±5.9 months after discharge from hospital. Medical adherence was evaluated using Morisky-Green questionnaire. Results. Mean age of patients was 73.9±10.0 years (male -52.6), CHA 2 DS 2 -VASc and HAS-BLED score were estimated as 5.14±1.50 и 1.59±0.79, respectively. Contraindications to OAC treatment were registered in 34 (11.9%) patients. In pre-hospital stage patients with paroxysmal AF received OAK more rarely comparing to those with permanent and persistent AF (31.8%, 51.7 and 55%, respectively; р<0.05). The rate of OAC administration in pre-hospital stage, on discharge and after 24.1±5.9 months follow-up period was 40.4%, 88.1% and 82%, respectively, whereas patients with previous stroke were prescribed OACs more frequently (in 49%, 92.5% and 83.7% of cases, respectively). Only 43% of study participants had good compliance to medical treatment (score of 4) according to Morisky-Green questionnaire. Conclusion. OACs were under prescribed in pre-hospital stage and after 2 years of follow-up in patients with AF combined with HT, IHD and CHF comparing with in-hospital period (40.4% and 82% vs 88.1%). Medical compliance according to Morisky-Green questionnaire was not enough (43%) in high-risk patients after discharge from hospital.Key words: atrial fibrillation, anticoagulation therapy, registry, treatment stages, compliance, comorbid cardiovascular diseases. Цель. Изучить частоту назначения оральных антикоагулянтов (ОАК), преемственность антикоагулянтной терапии на госпитальном и амбу-латорно-поликлиническом этапах, а также приверженность к медикаментозному лечению у больных с фибрилляцией предсердий (ФП) в сочетании с артериальной гипертонией (АГ), ишемической болезнью сердца (ИБС), хронической сердечной недостаточностью (ХСН) в рам-ках регистра сердечно-сосудистых заболеваний (ССЗ). Материал и методы. В данное исследование включены 285 больных с сочетанием ФП, АГ, ИБС и ХСН из регистра РЕКВАЗА-КЛИНИКА (n=3696). Назначение ОАК на амбулаторном этапе до госпитализации и в стационаре, оценивали на основании данных медицинской документации. На амбулаторном этапе после госпитализации (через 24,1±5,9 мес) оценка лекарственной терапии осуществлялась посредством телефон-ного контакта с 250 пациентами (96,2% от числа выживших пациентов в течение периода наблюдения). Приверженность...

show abstract

Section: Oral Anticoagulants In Ambulatory and In-hospital Treatment supporting

confidence: 84%

Oral Anticoagulants in Ambulatory and in-Hospital Treatment of Patients With Atrial Fibrillation Associated With Hypertension, Ischemic Heart Disease and Chronic Heart Failure: Data From Hospital Registry Recvasa-Clinic

Stepina¹,

Lukyanov²,

Бичурина³

et al. 2017

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

“…Indeed, in a comprehensive overview of studies conducted in patients with chronic conditions, adherence to the prescribed medications was found to be considerably lower for drugs requiring twice daily dosing than those requiring once daily dosing 31 . Similar results were found in a recent review of studies addressing the treatment of cardiovascular disorders 32 . The conclusions of this analysis are interesting and relevant to clinical practice, as they have the potential to have an impact on the prescription of NOAC agents.…”

supporting

confidence: 90%

Adherence to the novel oral anticoagulants: an unmet need

Prandoni

2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

“…Taken together, the above-mentioned data, as well as those demonstrating better adherence with less frequent dosing of cardiovascular medications including NOACs, 15 suggest that patient satisfaction may be optimized by utilizing a once-daily NOAC for stroke prevention in NVAF.…”

Section: Discussionmentioning

confidence: 91%

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy

Coleman

Haas²,

Turpie

et al. 2016

Clinical Cardiology

Self Cite

View full text Add to dashboard Cite

BackgroundThe efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation‐treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs).HypothesisTransitioning from a VKA to rivaroxaban improves treatment satisfaction in routine practice.MethodsXarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) is a prospective, noninterventional study in patients with NVAF prescribed rivaroxaban for prevention of stroke in routine practice. Patients receiving a VKA 4 weeks prior to the initial XANTUS study visit and switched to rivaroxaban were asked to complete the Anti‐Clot Treatment Scale (ACTS). Changes from the initial visit to the first follow‐up visit at ∼ 3 months (corresponding to a comparison of rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated using and reported as least squared mean differences (LSMDs) with 95% confidence intervals (CIs).ResultsThe study included 1291 NVAF patients with prior VKA treatment. The mean baseline ACTS burden and benefit scores were 50.51 ± 8.42 and 10.30 ± 2.70, respectively. After ∼ 3 months of rivaroxaban treatment, LSMDs were 4.38 points (95% CI: 2.53‐6.22, P < 0.0001) for the burden and 1.01 points (95% CI: 0.27‐1.75, P = 0.0075) for the benefit score. Fifty‐four percent and 48% of patients reported experiencing at least a minimally important clinical difference in burden and benefit scores, respectively.ConclusionsWithin this XANTUS cohort, switching from a VKA to rivaroxaban yielded statistically and clinically significant improvements in ACT burden and benefit scores.

show abstract

Effect of Dosing Frequency on Chronic Cardiovascular Disease Medication Adherence

Cited by 44 publications

References 0 publications

Oral Anticoagulants in Ambulatory and in-Hospital Treatment of Patients With Atrial Fibrillation Associated With Hypertension, Ischemic Heart Disease and Chronic Heart Failure: Data From Hospital Registry Recvasa-Clinic

Oral Anticoagulants in Ambulatory and in-Hospital Treatment of Patients With Atrial Fibrillation Associated With Hypertension, Ischemic Heart Disease and Chronic Heart Failure: Data From Hospital Registry Recvasa-Clinic

Adherence to the novel oral anticoagulants: an unmet need

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy

Contact Info

Product

Resources

About